English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

This letter is a report of a re-evaluation of the results obtained in an earlier study of ours (Balldin et al., 1994) of platelet monoamine oxidase (MAO)-B activity in alcoholics with reduced dopamine (DA) D 2 receptor function, as assessed by the growth hormone (GH) response to the D 1 /D 2 agonist apomorphine (APO), which was published in this journal. The reason for the re-evaluation of the results in our study is a Letter to the Editors of this journal by Farren and Dinan (1996) reporting on platelet MAO-B activity in alcoholics with reduced DA D 2 receptor function, as assessed by the GH response to the DA D 2 receptor agonist bromocriptine. In the report by Farren and Dinan (1996), four of eight alcoholics had no increase in GH above baseline, whereas all eight subjects in the control group had the expected GH response to bromocriptine. The authors compared platelet MAO-B activity in the four alcoholic subjects who had no increase in GH above baseline to that in the four alcoholics who had a significant increase in GH after bromocriptine. They found no significant difference in platelet MAO-B activity between these two groups and thus no evidence for altered platelet MAO-B activity in alcoholics with reduced DA D 2 receptor function. In their Letter to the Editors, Farren and Dinan (1996) made a very valuable comment with regard to our earlier study

ALCOHOL-DEPENDENT PATIENTS WITH NEUROENDOCRINE EVIDENCE FOR REDUCED DOPAMINE D2 RECEPTOR FUNCTION HAVE DECREASED PLATELET MONOAMINE OXIDASE-B ACTIVITY